The role of trust in the acceptance of adjuvant endocrine therapy in breast cancer patients

AbstractObjectiveDespite adjuvant endocrine therapy (AET) considerably reducing mortality and recurrence in hormonal receptor‐positive (HR+) breast cancer (BC) patients, acceptance of AET remains an issue. The reasoning behind the lack of acceptance is complex and multifactorial, and some associated risk factors have been previously analyzed. Our study aims to assess women's beliefs and concerns toward AET and women's trust in the treating physician, focusing on determining the importance of these factors in the acceptance of AET.MethodsOut of n = 539, n = 269 women with HR + BC participated in a cross‐sectional online survey. The main study variables were AET necessity beliefs and concerns (Beliefs about Medicines Questionnaire) and the trust in treating physicians. A binary hierarchical logistic regression was applied to predict AET acceptance.ResultsWe did not observe a meaningful mean difference in the necessity beliefs between women who accepted versus refused AET by the time of study conduct. Women with ongoing AET intake indicated significantly higher trust in their treating physician (d = 0.57) and have lower concerns (d = −1.65) regarding AET than women who had declined or discontinued AET prematurely. Results of the logistic regression demonstrated that after adjusting for clinical factors (e.g., prognosis, age), higher trust and lower concerns significantly increased the likelihood of accepting AET treatment.ConclusionsOur results demonstrate the importance of discussing potential concerns regarding AET and establishing a trustful patient‐physician relationship, which outweighs non‐modifiable factors such as cancer prognosis.